The Arteriosclerosis drugs in development market research report provides comprehensive information on the therapeutics under development for Arteriosclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Arteriosclerosis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Arteriosclerosis and features dormant and discontinued products.
GlobalData tracks 121 drugs in development for Arteriosclerosis by 104 companies/universities/institutes. The top development phase for Arteriosclerosis is preclinical with 73 drugs in that stage. The Arteriosclerosis pipeline has 96 drugs in development by companies and 25 by universities/ institutes. Some of the companies in the Arteriosclerosis pipeline products market are: Vasocure Therapeutics, Verve Therapeutics and Eli Lilly and Co.
The key targets in the Arteriosclerosis pipeline products market include Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.), Apolipoprotein A (APOA or LPA), and Angiopoietin Related Protein 3 (Angiopoietin 5 or Angiopoietin Like Protein 3 or ANG 5 or ANGPTL3).
The key mechanisms of action in the Arteriosclerosis pipeline product include Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) Inhibitor with ten drugs in Phase III. The Arteriosclerosis pipeline products include eight routes of administration with the top ROA being Oral and 18 key molecule types in the Arteriosclerosis pipeline products market including Small Molecule, and Monoclonal Antibody.
Arteriosclerosis overview
Arteriosclerosis refers to the thickening and hardening of arteries due to plaque buildup, limiting blood flow. Atherosclerosis, a common form, involves cholesterol and other substances accumulating in arterial walls, narrowing them. This condition heightens the risk of heart disease, stroke, and peripheral artery disease. Factors like high blood pressure, cholesterol, smoking, diabetes, and obesity contribute. Management involves lifestyle changes—such as a healthy diet and exercise—and medications to control risk factors. Sometimes, procedures like angioplasty or stent placement help restore blood flow. Preventive measures and early management play pivotal roles in reducing complications associated with arteriosclerosis.
For a complete picture of Arteriosclerosis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
